What is Alnylam Pharmaceuticals 6-1 Month Momentum %?
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2025-03-23), Alnylam Pharmaceuticals's 6-1 Month Momentum % is -8.50%.
The industry rank for Alnylam Pharmaceuticals's 6-1 Month Momentum % or its related term are showing as below:
ALNY's 6-1 Month Momentum % is ranked better than 51.22% of 1480
companies
in the Biotechnology industry
Industry Median: -9.63
vs ALNY: -8.50
Competitive Comparison of Alnylam Pharmaceuticals's 6-1 Month Momentum %
For the Biotechnology subindustry, Alnylam Pharmaceuticals's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals's 6-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Alnylam Pharmaceuticals 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALNY has been successfully added to your